The global gastrointestinal drugs market, a part of the healthcare industry, grew at a compound annual growth rate (CAGR) of around 3% during the historic period. The healthcare industry showed a steady growth. The growth is mainly due to the increasing gastro intestinal diseases caused by unhealthy lifestyle habits such as lack of physical activity, poor diet and others.
In the forecast period, the global gastrointestinal drugs market size is expected to be over $65 billion by 2021, growing at a CAGR of nearly 5%. This is expected due to the expected increase in prevalence of obesity and digestive diseases globally. Furthermore, rising population, increase in dispensable income, and increasing per capita incomes are expected to drive the global gastrointestinal drugs market in the future.
Find TBRC’s report on the Gastrointestinal Drugs market: https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market-report-2018
Drug manufacturing companies are offering tranexamic acid for the treatment of acute gastrointestinal bleeding. Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma or surgery and is now finding applications for gastrointestinal diseases. Tranexamic acid reduces clot breakdown, thus reducing the duration and amount of bleeding. Major companies in the gastrointestinal drugs market, offering new technology include Takeda Pharmaceuticals, Allergan Plc. And Novo Nordisk A/S.
Download a sample report: https://www.thebusinessresearchcompany.com/sample.aspx?id=273&type=smp
About The Business Research Company.
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
No comments:
Post a Comment